However, these studies examined patients with surgically resectable NSCLC, not those with advanced or recurrent cancer; thus, it is unknown whether the relationship between 18F-FDG uptake and the efficacy of anti-PD-1 mAbs is also true in more advanced disease. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.